Increased Risk of Intraocular Inflammation with Aflibercept Injections in Real-World Practice
Real-world use of aflibercept injections shows a higher incidence of mild intraocular inflammation compared to clinical trials, emphasizing the need for careful patient monitoring and education.
Recent research highlights that intraocular inflammation (IOI), a potential side effect of intravitreal aflibercept injections, appears to be more common in real-world clinical settings compared to controlled trials. A study published online on May 1, 2025, in JAMA Ophthalmology evaluated the occurrence of mild sterile IOI following aflibercept treatment.
The study, led by Dr. Karoline E. Binder from the Technical University of Munich, involved 41 patients receiving a total of 136 injections of 8 mg aflibercept, primarily for neovascular age-related macular degeneration and diabetic macular edema. The findings revealed that five patients developed mild sterile IOI within one to three days after injection. The incidence rate was approximately 3.7% per injection and 12% per patient. Notably, only one patient experienced inflammation after the initial dose, while the other four had prior injections.
All affected patients received localized anti-inflammatory treatments, such as topical or subconjunctival corticosteroids, with two also receiving systemic corticosteroids. Despite the inflammation, there was no impact on their visual acuity once the IOI resolved. The study authors emphasized that, although the observed IOI was mild, healthcare providers should carefully assess patient risk factors before treatment and ensure thorough patient education about potential side effects.
This research underscores the importance of vigilant monitoring during aflibercept therapy outside the controlled environment of clinical trials and highlights that mild intraocular inflammation is an important consideration in real-world practice.
Source: https://medicalxpress.com/news/2025-05-intraocular-inflammation-common-aflibercept-real.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Identifies Key Risk Factors for Second Colorectal Cancer in Lynch Syndrome Patients
A new study identifies key genetic and clinical factors that increase the risk of second colorectal cancer in Lynch syndrome patients, paving the way for personalized prevention and surveillance strategies.
Managing Blood Pressure in Non-Cardiac Surgery Shows Similar Neurocognitive Outcomes
A large international study finds that different blood pressure management strategies during non-cardiac surgery result in similar neurocognitive outcomes, offering greater flexibility in perioperative care.
Viral Strategy Uses Mitochondrial Remodeling to Evade Immune Response and Identify New Drug Opportunities
Scientists at The Wistar Institute have discovered how herpesviruses manipulate mitochondrial structure to evade immune responses, offering new drug development targets to treat virus-related diseases.
Innovative AI-Based Rapid Testing for Viral Infections
A new AI-driven nanopore test enables quick and accurate detection of live viruses within minutes, promising to enhance viral infection diagnosis and treatment.